News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
701,014 Results
Type
Article (41593)
Company Profile (463)
Press Release (658958)
Section
Business (208394)
Career Advice (2002)
Deals (35942)
Drug Delivery (92)
Drug Development (83302)
Employer Resources (169)
FDA (16325)
Job Trends (15043)
News (352082)
Policy (32979)
Tag
Academia (2619)
Alliances (50600)
Alzheimer's disease (1273)
Approvals (16250)
Artificial intelligence (139)
Bankruptcy (361)
Best Places to Work (11732)
Biotechnology (349)
Breast cancer (123)
Cancer (1109)
Cardiovascular disease (102)
Career advice (1671)
Cell therapy (247)
Clinical research (65989)
Collaboration (404)
Compensation (199)
COVID-19 (2590)
C-suite (100)
Data (1136)
Diabetes (156)
Diagnostics (6196)
Earnings (86042)
Employer resources (147)
Events (112903)
Executive appointments (313)
FDA (16865)
Funding (362)
Gene therapy (191)
GLP-1 (610)
Government (4408)
Healthcare (18995)
Infectious disease (2674)
Inflammatory bowel disease (113)
Interviews (308)
IPO (16571)
Job creations (3694)
Job search strategy (1428)
Layoffs (439)
Legal (7928)
Lung cancer (174)
Manufacturing (181)
Medical device (13322)
Medtech (13327)
Mergers & acquisitions (19431)
Metabolic disorders (423)
Neuroscience (1564)
NextGen Class of 2024 (6733)
Non-profit (4532)
Northern California (1494)
Obesity (242)
Opinion (198)
Patents (102)
People (57621)
Phase I (20676)
Phase II (29128)
Phase III (21546)
Pipeline (458)
Postmarket research (2590)
Preclinical (8877)
Radiopharmaceuticals (251)
Rare diseases (233)
Real estate (5998)
Regulatory (21956)
Research institute (2403)
Resumes & cover letters (351)
Southern California (1323)
Startups (3746)
United States (13800)
Vaccines (565)
Weight loss (182)
Date
Today (134)
Last 7 days (849)
Last 30 days (3844)
Last 365 days (36669)
2024 (33585)
2023 (41013)
2022 (52277)
2021 (56766)
2020 (54924)
2019 (47419)
2018 (35698)
2017 (33024)
2016 (32346)
2015 (38396)
2014 (32185)
2013 (27109)
2012 (29220)
2011 (29863)
2010 (27992)
Location
Africa (731)
Arizona (200)
Asia (38506)
Australia (6402)
California (3407)
Canada (1289)
China (250)
Colorado (146)
Connecticut (160)
Europe (83980)
Florida (458)
Georgia (116)
Illinois (351)
Indiana (198)
Kansas (99)
Maryland (588)
Massachusetts (2710)
Michigan (159)
Minnesota (277)
New Jersey (965)
New York (965)
North Carolina (754)
Northern California (1494)
Ohio (140)
Pennsylvania (847)
South America (1105)
Southern California (1323)
Texas (473)
Utah (92)
Washington State (371)
701,014 Results for "denali therapeutics inc".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Business
Denali Therapeutics Reports First Quarter 2024 Financial Results and Business Highlights
Denali Therapeutics Inc. reported financial results for the first quarter ended March 31, 2024, and provided business highlights.
May 7, 2024
·
13 min read
Press Releases
Denali Therapeutics Reports Third Quarter 2024 Financial Results and Business Highlights
November 7, 2024
·
15 min read
Press Releases
Semnur Pharmaceuticals, Inc., a Wholly Owned Subsidiary of Scilex Holding Company, Announces Today the Filing of a Registration Statement on Form S-4 by Denali Capital Acquisition Corp. with the Securities and Exchange Commission Relating to the Previously Announced Proposed Business Combination Between Semnur and Denali
November 7, 2024
·
13 min read
Biotech Bay
Denali Therapeutics Announces FDA Has Selected DNL126 (ETV:SGSH) for MPS IIIA (Sanfilippo Syndrome Type A) for START Pilot Program Intended to Accelerate Development of Rare Disease Therapies
Denali Therapeutics Inc. today announced that the U.S. Food and Drug Administration (FDA) has selected DNL126 for participation in the Support for clinical Trials Advancing Rare disease Therapeutics (START) Pilot Program.
June 3, 2024
·
9 min read
Deals
Denali Therapeutics Announces $500 million Private Placement Equity Financing
Denali Therapeutics Inc. today announced that the company has entered into a securities purchase agreement with certain existing accredited investors to issue and sell an aggregate of 3,244,689 shares of its common stock at a price of $17.07 per share.
February 27, 2024
·
6 min read
Business
Denali Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Business Highlights
Denali Therapeutics Inc. today reported financial results for the fourth quarter and year ended December 31, 2023, and provided business highlights.
February 27, 2024
·
17 min read
Drug Development
Denali Therapeutics Announces Completion of Enrollment for Regimen G Evaluating eIF2B Agonist DNL343 in the Phase 2/3 HEALEY ALS Platform Trial
Denali Therapeutics Inc. today announced that the Sean M. Healey & AMG Center in collaboration with the Northeast ALS Consortium (NEALS) completed enrollment for Regimen G of the Phase 2/3 HEALEY ALS Platform Trial.
May 1, 2024
·
5 min read
Multiple sclerosis
Sanofi, Denali Abandon Mid-Stage Multiple Sclerosis Study on Disappointing Data
Oditrasertib, which blocks the inflammatory RIPK1 protein, earlier this year also failed a Phase II trial in amyotrophic lateral sclerosis, forcing the company to discontinue its development a few months later.
October 11, 2024
·
2 min read
·
Tristan Manalac
Press Releases
Denali Therapeutics Reports Second Quarter 2024 Financial Results and Business Highlights
August 1, 2024
·
15 min read
Denali Secures $500M in Financing, Focuses on Large Molecule Biotherapeutics
On the heels of layoffs, Denali Therapeutics has entered into a securities purchase agreement with existing accredited investors as it spins off preclinical small molecule portfolio.
February 27, 2024
·
2 min read
·
Kate Goodwin
1 of 70,102
Next
